The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
What causes mental dysfunction in Parkinson's disease?
Abstract
Parkinson's disease (PD) is frequently associated with mental dysfunction. Domain-specific cognitive deficits are ubiquitous, and although they may not be clinically apparent in all patients, they are demonstrable by neuropsychological testing. Dementia is less frequent but is present significantly more in PD patients than in controls, with a cumulative prevalence rate up to 40% and up to six-fold increased incidence. Cognitive impairment mainly involves executive and visuospatial functions; memory is secondarily impaired with relatively preserved recognition. Qualitatively, the neuropsychological profile of dementia encompasses the same type of deficits found in nondemented PD patients. The dementia seen in PD, therefore, can be described as a dysexecutive syndrome combined with visuospatial dysfunction and behavioural symptoms. Dopaminergic, noradrenergic, serotoninergic, and cholinergic deficits have all been described as the underlying neurochemical impairment, but the strongest evidence exists for a cholinergic dysfunction. Involvement of brainstem nuclei, limbic structures, and cerebral cortex have been suggested as the site, and Lewy body (LB) degeneration and Alzheimer-type changes as the type of pathology underlying the mental dysfunction in PD. Although there is still some controversy as to the site and type of pathology, recent evidence suggests that LB-type degeneration in limbic structures and cerebral cortex, with consequent synaptic and cell loss, is the main pathological state associated with dementia in PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk of dementia in Parkinson’s disease: A community-based, prospective study
Aarsland, D., Andersen, K., Larsen, J. P., Lolk, A., Nielsen, H., & Kragh–Sørensen, P. (2001) · Neurology · doi:10.1212/wnl.56.6.730 · Cited by 721
Parkinson disease, dementia, and alzheimer disease: Clinicopathological correlations
Boller, F., Mizutani, T., Roessmann, U., & Gambetti, P. (1980) · Annals of Neurology · doi:10.1002/ana.410070408 · Cited by 451
Cited by
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., Adena, M. A., Halliday, G. M., & Morris, J. G. L. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,246
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
Chaudhuri, K. R., & Schapira, A. H. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70068-7 · Cited by 1,738
Dementia associated with Parkinson's disease
Emre, M. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00351-x · Cited by 685
Self-citationCognitive status correlates with neuropathologic stage in Parkinson disease
Braak, H., Rüb, U., Jansen Steur, E. N. H., Del Tredici, K., & de Vos, R. A. I. (2005) · Neurology · doi:10.1212/01.wnl.0000158422.41380.82 · Cited by 560
Strongly reduced volumes of putamen and thalamus in Alzheimer’s disease: an MRI study
de Jong, L. W., van der Hiele, K., Veer, I. M., Houwing, J. J., Westendorp, R. G. J., Bollen, E. L. E. M., de Bruin, P. W., Middelkoop, H. A. M., van Buchem, M. A., & van der Grond, J. (2008) · Brain · doi:10.1093/brain/awn278 · Cited by 557
Priorities in Parkinson's disease research
Meissner, W. G., Frasier, M., Gasser, T., Goetz, C. G., Lozano, A., Piccini, P., Obeso, J. A., Rascol, O., Schapira, A., Voon, V., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3430 · Cited by 436
Changes in motor subtype and risk for incident dementia in Parkinson's disease
Alves, G., Larsen, J. P., Emre, M., Wentzel‐Larsen, T., & Aarsland, D. (2006) · Movement Disorders · doi:10.1002/mds.20897 · Cited by 434
Self-citationMetabolic brain networks associated with cognitive function in Parkinson's disease
Huang, C., Mattis, P., Tang, C., Perrine, K., Carbon, M., & Eidelberg, D. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2006.09.003 · Cited by 361
Scales to assess sleep impairment in Parkinson's disease: Critique and recommendations
Högl, B., Arnulf, I., Comella, C., Ferreira, J., Iranzo, A., Tilley, B., Trenkwalder, C., Poewe, W., Rascol, O., Sampaio, C., et al. (2010) · Movement Disorders · doi:10.1002/mds.23190 · Cited by 268
Dopamine dysregulation syndrome in Parkinson's disease
Evans, A. H., & Lees, A. J. (2004) · Current Opinion in Neurology · doi:10.1097/01.wco.0000137528.23126.41 · Cited by 257
Riedel, O., Klotsche, J., Spottke, A., Deuschl, G., Förstl, H., Henn, F., Heuser, I., Oertel, W., Reichmann, H., Riederer, P., et al. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0720-2 · Cited by 254
Cruise, K. E., Bucks, R. S., Loftus, A. M., Newton, R. U., Pegoraro, R., & Thomas, M. G. (2011) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2010.01338.x · Cited by 229
Psychiatric aspects of Parkinson?s disease: An Update
Schrag, A. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0483-3 · Cited by 200
Staffaroni, A., Elahi, F., McDermott, D., Marton, K., Karageorgiou, E., Sacco, S., Paoletti, M., Caverzasi, E., Hess, C., Rosen, H., et al. (2017) · Seminars in Neurology · doi:10.1055/s-0037-1608808 · Cited by 91
Early-Stage Identification and Pathological Development of Alzheimer’s Disease Using Multimodal MRI
Yan, T., Wang, Y., Weng, Z., Du, W., Liu, T., Chen, D., Li, X., Wu, J., & Han, Y. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-181049 · Cited by 59
Treatment of behavioural symptoms and dementia in Parkinson's disease
Hanagasi, H. A., & Emre, M. (2005) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2005.00317.x · Cited by 24
Self-citation
Metadata
- Authors
- Emre, M.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2003-09
- Volume
- 18
- Issue
- S6
- Pages
- 63-71
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2037062291
- Cited by
- 182
- References
- 2
- FWCI
- 5.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.